Thirdly, the question of whether serum YKL-40 in tumor patients is derived from production and release by the tumor cells themselves or from immune and/or stromal cells due to the tumor's immunologic reaction is a matter of debate [10]. The gene discussed is CHI3L1; the disease is neoplasm.